PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology

Neoadjuvant immuno-chemotherapy in resectable non-small cell lung cancer: A retrospective cohort study.

View Full Paper
Ask AI
Bookmark
Share

Authors

SVSaurav VermaMVMark VincentMBMorgan Black

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Verma et al. (2024) studied this question.

synapsesocial.com/papers/68e66db9b6db6435875f88cahttps://doi.org/10.1200/jco.2024.42.16_suppl.e20077
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world experience with neoadjuvant chemoimmunotherapy in resectable NSCLC: A single academic institution experience.2026
  2. 2Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer2024 · 2 citations
  3. 3Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.2024 · 62 citations
  4. 4Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice2024 · 8 citations
  5. 5322eP Surgical and clinical outcomes of major lung resection post systemic neoadjuvant therapy: A single-center retrospective analysis2026